Aktis Oncology (NASDAQ:AKTS) Hits New 52-Week High – Time to Buy?

Aktis Oncology (NASDAQ:AKTS) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $29.50 and last traded at $30.7050, with a volume of 828 shares traded. The stock had previously closed at $28.70.

Analyst Upgrades and Downgrades

AKTS has been the subject of several research reports. HC Wainwright raised their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Raymond James Financial initiated coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 target price for the company. William Blair initiated coverage on shares of Aktis Oncology in a research note on Wednesday, April 29th. They set an “outperform” rating for the company. Finally, Weiss Ratings upgraded shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $34.00.

Aktis Oncology Price Performance

The company has a 50 day moving average price of $20.89.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The firm had revenue of $1.87 million for the quarter. Equities analysts expect that Aktis Oncology will post -1.62 EPS for the current fiscal year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.